Compare Gilead Sciences, Inc. (GILD) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs PubMatic Inc — how do they compare? Gilead Sciences, Inc. trades at $133.6 (market cap $163.51B), while PubMatic Inc trades at $13.66 (market cap $640.22M). The key difference: Gilead Sciences, Inc. is far larger — about 255.4× PubMatic Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| GILD | PUBM | |
|---|---|---|
Market Cap | $163.51B | $640.22M |
Sector | Health | Technology |
52-Week High | $155.80 | $13.83 |
52-Week Low | $108.22 | $6.28 |
Enterprise Value | $178.05B | $537.73M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
PubMatic trades at $13.69, up 0.88% with a bullish technical signal from moving averages. The company shows strong revenue stability around $283M (2025) and positive operating cash flow of $81M, though net income remains negative at -$14.46M. Recent product launches like AgenticOS and partnerships signal innovation in digital advertising. Analyst consensus is evenly split between Buy and Hold with a $17 price target, indicating moderate upside potential from current levels.
The outlook balances growth initiatives against profitability challenges. Investment opportunity lies in market share gains from AI-driven ad tech expansion, but risks include persistent negative margins and competitive pressure. Valuation metrics (P/E 132) suggest high expectations that require execution to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
